| Document |
Document Title |
|
WO/2015/013865A1 |
Disclosed are agomelatine sulfonic acids complexes having the specific stoichiometry of 2 molar equivalents of agomelatine for 1 molar equivalent of sulfonic acids. Those complexes show excellent solubility, stability and purity, making ...
|
|
WO/2015/013903A1 |
The present invention relates to the p-toluenesulfonic acid co-crystals of agomelatine of formula (I), preparation and use thereof, and to pharmaceutical composition containing it. The p-toluenesulfonic acid co-crystals of agomelatine ob...
|
|
WO/2015/011032A1 |
The present invention relates to a process for preparing substituted biphenylanilides of the formula I in which R1 is selected from a protected amino group, NO2, NH2 and NHR3, in which a compound of the formula II is reacted in the prese...
|
|
WO/2015/012259A1 |
Provided is a reaction accelerator used in a reaction between a compound having an isocyanate group that does not directly bond to an aromatic ring, in each molecule, and a compound having an active hydrogren-containing group. The reacti...
|
|
WO/2015/011264A1 |
The present invention relates to improved powderous formulations comprising organic acid amides having an aromatic ring system as well as to the production of such formulations.
|
|
WO/2015/009977A1 |
The present invention provides a compound of formula (I), a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ...
|
|
WO/2015/007388A1 |
The invention relates to a salt of (E)-N-((1s,4s)-4-(dimethylamino)-1,4-diphenylcyclohexyl)-N-m
ethylcinnamamide.
|
|
WO/2015/007909A1 |
The invention relates to a thermal conversion vessel (200) used during amidification step of acetone cyanohydrin (ACH), in the industrial process for production of a methyl methacrylate (MMA) or methacrylic acid (MAA). The thermal conver...
|
|
WO/2015/007897A1 |
The present invention provides a very simple, efficient and economic technology for racemisation of amines, alcohols or thioalcohols where the chiral carbon (benzylic position) is located at the β-position of the heteroatom (amino, hydr...
|
|
WO/2015/003615A1 |
The present invention provides simultaneously an acyl(-N,N-dialkyl) diamine surfactant and a preparation method of the surfactant. The method uses an oleic acid as an initial reactant, followed by an alkylation reaction, an chloroformyla...
|
|
WO/2015/003951A1 |
Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.
|
|
WO/2015/000555A2 |
The present invention relates to a novel process for the preparation or tetralin and naphthalene derivatives, including Agomelatine and pharmaceutical acceptable salts thereof. Such compounds are considered to be interesting either as us...
|
|
WO/2014/207343A1 |
The invention concerns a fatty amide-based hydrogelling additive, produced from the addition reaction of a fatty acid R1CO2H on caprolatam, which product carries a terminal carboxylic function in the form of an acid or in the form salifi...
|
|
WO/2014/208380A1 |
Provided are a compound for thickening or gelling a fluid organic material to the desired viscosity or uniformly stabilizing a composition containing a fluid organic material, a thickening agent containing the compound, a thickened compo...
|
|
WO/2014/202765A1 |
The present invention provides an asymmetric and economic synthesis of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H-benzo[d]azepine via novel intermediates applying an asymmetric enzymatic, biomimetic or catalytic reduction. The present inve...
|
|
WO/2014/199960A1 |
The present invention provides a novel compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which is useful for prophylaxis or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive imp...
|
|
WO/2014/200094A1 |
[Problem] To provide a novel production method for a stereoselective, optically active alcohol compound. [Solution] From the compound represented by formula (3), the optically active alcohol compound represented by formula (8) can be pro...
|
|
WO/2014/196482A1 |
The present invention provides: a composition for forming a gate insulating film that improves the insulating reliability of an organic thin film transistor without greatly reducing the mobility of the organic thin film transistor; an or...
|
|
WO/2014/191090A1 |
The present invention relates to a mixture containing tertiary isononanoic acids, starting from 2-ethylhexanol, to the production thereof by dehydration of 2-ethylhexanol to give an octene mixture and subsequent hydroxycarboxylation with...
|
|
WO/2014/187229A1 |
The present invention provides a preparation method for agomelatine crystal form I. In the preparation method, agomelatine is used as the raw material, and a polymer auxiliary material such as polyvinylpyrrolidone or hydroxy propyl methy...
|
|
WO/2014/183221A1 |
Resveratrol analogs and their use to inhibit Kv1.5 channels are provided. The resveratrol analogs are useful in the treatment of atrial arrhythmias, including atrial fibrillation (AF). Exemplary resveratrol analogs are compounds of gener...
|
|
WO/2014/179943A1 |
The present invention relates to a maleic amide compound. The maleic amide compound is a compound with a general formula (I) or a pharmaceutical salt thereof. The maleic amide compound is used for preparing a medicament for treating a sk...
|
|
WO/2014/175136A1 |
The objective of the present invention is to provide: an optical film which is substantially capable of providing λ/4 retardation, while being suppressed in changes in the optical performance due to humidity changes, and which also has ...
|
|
WO/2014/173928A1 |
The present invention is directed to a simple and economical process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine via novel intermediates and a highly selective asymmetric synthesis leading to enantiopur...
|
|
WO/2014/170413A1 |
The present invention relates to a compound of formula (I): wherein the substituents are as defined herein, and wherein the compound of formula (I) is optionally present as an agrochemically acceptable salt thereof. These compounds are t...
|
|
WO/2014/167481A1 |
The present invention relates to novel synthetic analogues of xanthohumol and the use thereof.
|
|
WO/2014/161850A1 |
The present invention provides a novel and improved process for the production of the production of hindered anilines containing perfluoroalky groups in good yield any by using close to stoichiometric amounts of acylating agent.
|
|
WO/2014/165827A1 |
Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demye...
|
|
WO/2014/164667A1 |
Compounds and methods of treating or preventing a Flavivirus infection in a subject are provided. The methods comprise administering to the subject a therapeutically effective amount of a compound as described herein. The methods are use...
|
|
WO/2014/164867A1 |
Disclosed herein are new compounds and compositions and their application as pharmaceuticals for the treatment of diseases. Methods of inhibition of KDMIA, and methods of increasing gamma globin gene expression in a human or animal subje...
|
|
WO/2014/158597A1 |
A compound having a plurality of (meth)acrylate functional groups may be a ((meth)acryloylalkyl)amide. Preferably the compound having a plurality of (meth)acrylate functional groups is derived from a natural oil. More preferably the comp...
|
|
WO/2014/158654A1 |
Compounds of formula (II): wherein A, R1, R2, R5 and R13 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well...
|
|
WO/2014/148136A1 |
The purpose is to provide a novel compound for suppressing both IgE production and mast cell activation, and the use thereof. Provided is a novel compound that (1) is a derivative of a medium-chain fatty acid having 10 or 11 carbon atoms...
|
|
WO/2014/149819A1 |
Analgesic compounds for treatment of pain or fever that include a bicyclopentane moiety linked to an amine, combinations of the compounds with opioid analgesic drugs, and methods for treating pain or fever by administering a compound des...
|
|
WO/2014/150677A1 |
There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, vi...
|
|
WO/2014/139963A1 |
The invention is directed to a cosmetic composition and the precursor thereof. The composition has solid agent and liquid agent, both of which are cosmetic benefit ingredients. The solubility of solid agents in liquid agents in the inven...
|
|
WO/2014/139870A1 |
The present invention provides a method for selectively controlling or modifying the growth of Poa annua in cool-season turf grass without causing significant injury to the turfgrass, comprising applying to the turf grass or to locus of ...
|
|
WO/2014/143561A1 |
Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may b...
|
|
WO/2014/142116A1 |
Provided are: a ceramide-like function imparting agent which imparts a function similar to that of a ceramide; a skin barrier function reinforcing agent; a moisturizing agent; and an external preparation for the skin. A ceramide-like fun...
|
|
WO/2014/145693A1 |
The invention relates to metabolites of foretinib (I) as well as uses thereof.
|
|
WO/2014/145715A1 |
The invention relates to metabolites of cabozantinib (I) as well as uses thereof.
|
|
WO/2014/136914A1 |
The provision of an oxygen-absorbing multilayer body that has the following: an oxygen-absorption layer that contains an oxygen-absorbing composition; and a thermoplastic-resin layer that contains a thermoplastic resin (b). The oxygen-ab...
|
|
WO/2014/138053A1 |
In one aspect, the invention relates to compounds having the formula: (I) where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In anoth...
|
|
WO/2014/136918A1 |
The provision of an oxygen-absorbing medical multiwall container that has at least the following three layers, in this order: a first resin layer containing a thermoplastic resin (b1); an oxygen-absorption layer containing an oxygen-abso...
|
|
WO/2014/131572A1 |
Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.
|
|
WO/2014/132270A2 |
The present invention relates to a process for the preparation of 2-(2-aminothiazol-4-yl)- N-[4-(2- {[(2R)-2-hydroxy-2-phenylethyl]amino} ethyl)phenyl]acetamide monohydrochloride compound of formula- la, its intermediates and polymorph t...
|
|
WO/2014/131514A1 |
A composition comprising amide amines of the formula (I) R-C(O)-NH-(CH2)3-N(CH3)2 in which R-C(O) represents the aliphatic acyl residues of a natural wax oxidate is suitable for production of cosmetic compositions, especially of haircare...
|
|
WO/2014/128333A1 |
The invention is of interest to the pharmaceutical sector. It relates to novel therapeutic formulations based on nanoemulsions of plant oils as a system for transporting pharmaceuticals derived from N-acylethanolamines (NAEs) for the adm...
|
|
WO/2014/129874A1 |
The present invention relates to: a novel α,β-unsaturated amide compound; a method for preparing a composition for preventing or treating obesity, comprising the steps of selecting a compound showing an obesity prevention or treatment ...
|
|
WO/2014/125145A1 |
The invention relates to a novel method for modifying hydroxylated cyclic amino acids, especially 4-hydroxyproline, which is a commercial, relatively cheap, natural amino acid, in order to provide other amino acids of high optical purity...
|
